View as “PDF version”
We’ve
done many columns on misdiagnoses due to laboratory errors. Most have dealt
with issues such as incorrect specimen labeling or lost specimens. But in
several columns, we noted misdiagnoses due to contamination of tissue specimen
slides with tissue from a specimen from another patient. In our January 22,
2013 Patient Safety Tip of the Week “You
Don’t Know What You Don’t Know” we discussed the possibility that you might
have a biopsy specimen which was either not yours or was yours but also had
some tissue from another patient on the slide(s). Such errors are known as occult
specimen provenance complications (SPC’s). In that Tip we noted a study
providing an estimate of how often such SPC’s occur (Pfeifer
2013). They examined about 13,000 prostate biopsy
specimens from a wide variety of urology practices and pathology laboratories
using a DNA identification technology. They found the frequency of occult type
1 errors (a complete transposition between patients) was 0.26% and type 2
errors (contamination of the patient’s tissue with 1 or more unrelated
patients) was 0.67%. Overall, the mean frequency of SPCs across practice
settings was 0.22% for type 1 errors and 1.69% for type 2 errors.
Our March 24, 2015 Patient Safety Tip of the
Week “Specimen
Issues in Prostate Cancer”
noted a study (Wojno 2015) that
estimated the potential economic impact of such errors.
The
July 2022 issue of the American Journal of Clinical Pathology contained a study
that really opened our eyes to the issue of specimen contamination. Carll et al. (Carll 2022) noted that, after some laboratory changes
due to hospital construction, some cases were found to be affected by “carryovers”
(contaminants that are incorporated into the paraffin block). They note that incorporation
into a block makes identification of a contaminant more difficult, as the
contaminant will often be present in multiple cut levels and typically lack the
artifactual morphologic features that characterize “floaters” (the more common
type of contaminant that occurs when thin-cut tissue sections transfer to
inappropriate slides).
Fortunately,
the pathologists at this hospital were able to identify the contamination and
no patients were impacted. But the occurrence led to an investigation to
determine the underlying causes.
Carryovers
indicate contamination at or before the point of tissue embedding and have
usually been attributed to either the grossing bench or the embedding station.
But they were able to rule out contamination at the bench or embedding station.
They suspected that the contamination may have occurred during tissue transport
through a pneumatic tube system that had been required during the recent
hospital construction.
So, they
did an interesting experiment to assess that possibility. Cassettes of friable
donor tissue were mixed with cassettes of spongy recipient tissue in
formalin-filled containers and agitated by shipment via pneumatic tube. The
tissue cassettes were processed, embedded as blocks, and cut as usual. Liquid
samples were prepared from the submission containers as well as from
workstation submission containers and histology tissue processor waste.
They
found a high rate of contamination (14.9%) under these artificial conditions.
Friable donor tissue, including urothelium and colorectal adenocarcinoma, and
placental villi were common contaminants, and fluid from submission containers
showed viable tumor cells and fragments.
This
study implicates liquid transport media as a possible avenue of contamination
during submission and transportation of tissue cassettes for histologic
processing. Attention should be given to the friability of submitted tissue and
physical agitation of the cassettes in transit. Such contaminants may be
present in the fluid in tissue submission bins and in tissue processor fluid.
That
finding certainly has practical implications. They concluded that agitation of
fluid sloshing back and forth between and through cassettes during transport presumably
can dislodge small fragments of friable tissue that may subsequently get trapped
within tissue submitted in other cassettes. While few labs probably still
transport specimens via pneumatic tubes, presumably any method of transport
that has significant agitation could produce similar contamination. They note
that couriers using carts or motor vehicles to transport specimens may produce
some degree of physical agitation that could be similar to
that produced by the pneumatic tube transport.
The
authors encourage anatomic pathology labs to review their submission and
transportation protocols to identify possible sources of tissue contamination
and to improve quality and safety outcomes.
In an
editorial accompanying the Carll study, Zarbo (Zarbo 2022) discusses the numerous steps in which
contamination of pathology specimens might occur and concludes “it is safe to
conclude that tissue contamination occurs daily, everywhere surgical pathology
is practiced, despite good intention, written procedures, staff education,
competency assessments, and regulatory requirements crafted to promote safety.”
He says it is imperative that pathologists be ever suspicious and adopt the
“trust but verify” approach to microscopic diagnosis. He notes that when the
observations don’t seem to be compatible with the clinical context, we can stop
and verify a suspected tissue misidentity with
molecular DNA fingerprinting of even tiny amounts of tissue in doubt. But he
acknowledges that an unsuspected contaminant that appears to make sense in the
microscopic context of the case creates a dangerous problem.
In
one of our earliest columns on lab errors (see our October 9, 2007 Patient
Safety Tip of the Week “Errors
in the Laboratory“) we noted a paper (Suba
2007) that suggested we consider the “DNA timeout”
akin to the surgical timeout where we ask the question “Is this the correct
diagnosis for the correct patient?” before doing an invasive procedure.
Zarbo laments that” the open and communal systems, numerous
manual touches, and reused tools requiring voluntary and imprecise manual
wiping to clean between patients are not a sound basis to guarantee a process
that is free from contamination.” He concludes that it is time for a radical
redesign of the processes involved.
Some of our other columns on errors related
to laboratory studies:
References:
Pfeifer
JD, Liu J. Rate of Occult Specimen Provenance Complications in Routine Clinical
Practice. Am J Clin Path 2013; 139: 93-100
https://academic.oup.com/ajcp/article/139/1/93/1766518
Wojno K, Hornberger J, Schellhammer
P, et al. The Clinical and Economic Implications of Specimen Provenance
Complications in Diagnostic Prostate Biopsies. Journal of Urology 2015;
Published online: November 13, 2014
https://www.auajournals.org/article/S0022-5347%2814%2904864-2/abstract
Carll T, Fuja C, Antic T, et al.
Tissue Contamination During Transportation of Formalin-Fixed, Paraffin-Embedded
Blocks. American Journal of Clinical Pathology 2022; 158(1): 96-104
https://academic.oup.com/ajcp/article-abstract/158/1/96/6534995?redirectedFrom=fulltext&login=false
Zarbo RJ. The Unsafe Archaic Processes of Tissue Pathology:
Manifesto for Change. American Journal of Clinical Pathology 2022; 158(1): 4-7
https://academic.oup.com/ajcp/article-abstract/158/1/4/6540054?redirectedFrom=fulltext&login=false
Suba
EJ, Pfeifer JD, Raab SS. Patient Identification Error
Among Prostate Needle Core Biopsy Specimens—Are We Ready for a DNA Time-Out? J Urol 2007; 178(4): 1245-1248
https://www.auajournals.org/article/S0022-5347%2807%2901423-1/abstract
Print
“PDF
version”
http://www.patientsafetysolutions.com/